Cargando…
Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer
The advent of checkpoint blockade-based immunotherapy is rapidly changing the management of lung cancer. Whereas past anticancer drugs’ primary toxicity was hematologic, the newer agents have primarily autoimmune toxicity. Thus, it is no longer enough for oncology practitioners to be skilled only in...
Autores principales: | Green, Hannah Elizabeth, Nieva, Jorge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478790/ https://www.ncbi.nlm.nih.gov/pubmed/34127515 http://dx.doi.org/10.1136/jim-2021-001806 |
Ejemplares similares
-
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
por: Burke, Michael, et al.
Publicado: (2021) -
The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Gao, Weitong, et al.
Publicado: (2023) -
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017) -
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022) -
The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)